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Background: The Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) is a global surveillance study of antimicrobial
susceptibility. This study reports data from Gram-negative isolates collected from centers in Latin America between
2004 and 2010.
Methods: Consecutive bacterial isolates were tested at each center using broth microdilution methodology as
described by the Clinical Laboratory Standards Institute (CLSI). Susceptibility was determined using the CLSI
interpretive criteria. For tigecycline the US Federal Drug Administration (FDA) criteria were used.
Results: A total of 16 232 isolates were analyzed. Susceptibility to imipenem, meropenem, and tigecycline was
>95% against both non-extended-spectrum β-lactamase (ESBL) and ESBL producing Escherichia coli. Susceptibility to
amikacin was also >95% for non-ESBL E. coli. 24.3% of E. coli were ESBL producers, ranging from 11.2% (58/519) in
Colombia to 40.3% (31/77) in Honduras. Greater than 90% of non-ESBL Klebsiella pneumoniae were susceptible to
tigecycline, carbapenems and amikacin. 35.3% of K. pneumoniae were ESBL producers, ranging from 17.2% (36/209)
in Venezuela to 73.3% (55/75) in Honduras, with only imipenem and tigecycline maintaining >90% susceptibility.
Greater than 90% of Klebsiella oxytoca, Enterobacter spp., and Serratia marcescens were susceptible to amikacin,
carbapenems and tigecycline. The highest rates of susceptibility against Acinetobacter baumannii were seen for
minocycline (89.4%) and imipenem (62.5%), while 95.8% of the A. baumannii isolates displayed an MIC ≤2 μg/mL
for tigecycline.
Conclusions: In this study carbapenems and tigecycline remain active against Enterobacteriaceae and A.
baumannii; however, there is cause for concern with carbapenem non-susceptible isolates reported in all countries
included in this study.
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Tigecycline is a glycylcycline licensed by the US Food
and Drug Administration (FDA) for the treatment of
complicated skin and skin structure infections (cSSSI),
complicated intra-abdominal infections (cIAIs) and com-
munity acquired bacterial pneumonia (CAP). The Tige-
cycline Evaluation and Surveillance Trial (T.E.S.T.) is a
global surveillance study with the aim of assessing and
reporting the antimicrobial susceptibility of tigecycline
and comparator agents globally, regionally, and for* Correspondence: lfcanigia@labdl.com.ar
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use, distribution, and reproduction in any medindividual countries. T.E.S.T. was initiated in 2004 and
to date 60 countries have contributed with Gram-
positive and Gram-negative isolates and susceptibility
data. Antimicrobial surveillance studies, such as T.E.S.T.,
play a key role in charting antimicrobial resistance.
The Latin American region is recognized as facing a
significant challenge with high levels of antimicrobial
resistance among important Gram-negative organisms
including Escherichia coli and Klebsiella spp. and the
non-fermenters Acinetobacter spp. and Pseudomonas
aeruginosa [1-3]. In recent years, extended-spectrum β-
lactamases (ESBLs) have increased in type and frequency
among Enterobacteriaceae and carbapenemases have
emerged [4,5]. In the case of the non-fermentativensee BioMed Central Ltd. This is an Open Access article distributed under the
icense (http://creativecommons.org/licenses/by/2.0), which permits unrestricted
ium, provided the original work is properly cited.
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ing problem with limited, or no treatment option [6].
In this report we present data from the Latin American
region of Gram-negative isolates collected between 2004
and 2010. The isolates collected between 2004 and 2007
were previously reported by Rossi et al. [7].Methods
Organism collection
Gram-negative isolates were collected from 12 coun-
tries in Latin America between 2004 and 2010. Centers
were distributed as follows: 12 in Argentina, 3 in Brazil,
5 in Chile, 14 in Colombia, 1 in El Salvador, 4 in Guatemala,
2 in Honduras, 1 in Jamaica, 15 in Mexico, 1 in Nicaragua,
2 in Panama, and 6 in Venezuela. The Gram-negative iso-
lates submitted were consecutive and determined to be
clinically significant using local criteria. Permissible clini-
cal sources included blood, respiratory tract, urine (limited
to no more than 25% of all isolates), skin, wound, and
fluids. For each year, each participant center was required
to identify and conduct susceptibility tests on Acinetobac-
ter spp. (15), E. coli (25), Enterobacter spp. (25), Serratia
spp. (10), Klebsiella spp. (25) and Haemophylus influenzae
(15). A single isolate per patient was accepted. Inclusion
in the study was independent of the patient’s medical his-
tory, previous antimicrobial use, sex and age. No banked
or stored isolates were accepted.Antimicrobial susceptibility testing
Each study center carried out antimicrobial susceptibility
testing using broth microdilution methodology (SensititreW
plates [TREK Diagnostic Systems, West Sussex, England]
or MicroScanW panels [Siemens, Sacramento, CA, USA])
as described by the Clinical and Laboratory Standards
Institute (CLSI) [8]. Gram-negative isolates were tested
against amikacin, amoxicillin-clavulanate, ampicillin,
cefepime, ceftazidime, ceftriaxone, imipenem, levofloxa-
cin, meropenem, minocycline, piperacillin-tazobactam,
and tigecycline. In 2006, unreliability of the imipenem
testing led to a switch from MicroScanW panels with
imipenem to SensititreW plates with meropenem. The
presence or abscence of β-lactamase among H. influen-
zae was determined using the preferred method of each
center.
Quality control strains used in the testing were E. coli
ATCC 25922 and P. aeruginosa ATCC 27853. Confirm-
ation of isolate identification and management of a cen-
tralized database were performed by a central laboratory
(Laboratories International for Microbiology Studies, a
division of International Health Management Associates,
Inc. [IHMA, Schaumburg, IL, USA]).
Antimicrobial susceptibility was determined using
CLSI interpretive criteria [9,10]. For tigecycline, the FDAapproved breakpoints, as provided in the package insert,
were used [11].
Extended spectrum β-lactamase (ESBL) determination
Testing for ESBL production was carried out on isolates
of E. coli and Klebsiella spp. according to the CLSI guide-
lines [9]. The methodology used Mueller-Hinton agar
(Remel, Inc., Lenexa, KS, USA) and cefotaxime (30 μg),
cefotaxime-clavulanic acid (30/10 μg), ceftazidime (30
μg), and ceftazidime-clavulanic acid (30/10 μg) discs
(Oxoid, Inc., Ogdensburg, NY, USA). Quality control was
carried out using K. pneumoniae ATCC 700603 (ESBL-
positive) and E. coli ATCC 25922 (ESBL-negative).
Multidrug-resistant Acinetobacter baumannii
Multidrug resistance among isolates of A. baumannii
was defined as resistance to levofloxacin, amikacin, car-
bapenems (imipenem and/or meropenem), ceftazidime
and piperacillin-tazobactam.
Results
Antimicrobial susceptibility data on 16 232 Gram-
negative isolates collected in Latin America between
2004 and 2010 are presented in Table 1. Susceptibility
among the E. coli isolates (both ESBL and non-ESBL
producers) was >95% for carbapenems and tigecycline.
Susceptibility to amikacin was also >95% against non-
ESBL producing E. coli (MIC90 8 μg/mL) but decreased
to 89.7% against ESBL producers (MIC90 32 μg/mL). A
total of 24.3% of the E. coli collected from Latin America
were identified as ESBL producers with percentages of
ESBL production varying from 11.2% (58/519) in Co-
lombia to 40.3% (31/77) in Honduras (Figure 1). Data on
susceptibility to imipenem and meropenem by country
are presented in Table 2. Among E. coli isolates, ESBL
producers displayed slightly lower susceptibility to mero-
penem than non-ESBL producing isolates.
The most active antimicrobial agents against non-
ESBL producing K. pneumoniae were tigecycline (MIC90
1 μg/mL), carbapenems (imipenem MIC90 0.5 μg/mL
and meropenem MIC90 0.25 μg/mL) and amikacin
(MIC90 8 μg/mL) (Table 1). All tested antimicrobial agents
displayed reduced activity against ESBL-producing
K. pneumoniae, with only imipenem and tigecycline
recording percentage susceptibilities of >90% (96.0% and
93.7%, respectively). In particular, susceptibilities to levo-
floxacin against ESBL-producing isolates of E. coli and
K. pneumoniae were lower when compared with non-
ESBL-producing strains (11.5% vs. 60.9% and 38.2% vs
80.1%, respectively) (Table 1). Among K. pneumoniae
35.3% were ESBL producers and percentages ranged from
17.2% (36/209) in Venezuela to 73.3% (55/75)
in Honduras (Figure 1). Both ESBL and non-ESBL-
Table 1 Antimicrobial activity against Gram-negative organisms collected from Latin America (2004 – 2010)
Organisms/antimicrobial MIC (mg/L) Percentage
N 50 90 Range S I R
non-ESBL E. coli
Amikacin 2711 2 8 ≤0.5 to ≥128 97.2 1.2 1.7
Amoxi/clav 2711 8 32 ≤0.12 to ≥64 60.5 21.2 18.4
Ampicillin 2711 ≥64 ≥64 ≤0.5 to ≥64 28.6 1.5 69.9
Cefepime 2711 ≤0.5 4 ≤0.5 to ≥64 94.3 2.1 3.6
Ceftazidimea 2711 ≤8 16 ≤1 to ≥64 - - 11.7
Ceftriaxone 2711 ≤0.06 32 ≤0.06 to ≥128 82.0 2.3 15.6
Imipenem 485 0.25 0.5 ≤0.06 to ≥32 98.6 0.6 0.8
Levofloxacin 2711 0.25 ≥16 ≤0.008 to ≥16 60.9 3.0 36.2
Meropenem 2226 ≤0.06 0.12 ≤0.06 to ≥32 98.6 0.4 1.0
Minocycline 2711 4 16 ≤0.5 to ≥32 62.4 14.3 23.2
Pip/taz 2711 2 32 ≤0.06 to ≥256 88.8 5.2 6.0
Tigecycline 2711 0.25 0.5 ≤0.008 to ≥32 99.7 0.2 <0.1c
ESBL E. coli
Amikacin 870 4 32 ≤0.5 to ≥128 89.7 5.1 5.3
Amoxi/clav 870 16 32 0.25 to ≥64 21.1 42.5 36.3
Cefepime 870 32 ≥64 ≤0.5 to ≥64 28.2 14.3 57.6
Ceftazidimea 870 16 ≥64 ≤1 to ≥64 - - 65.5
Ceftriaxone 870 ≥128 ≥128 ≤0.06 to ≥128 1.1 2.0 96.9
Imipenem 143 0.25 0.5 ≤0.06 to 8 97.9 0.7 1.4
Levofloxacin 870 ≥16 ≥16 0.015 to ≥16 11.5 3.4 85.1
Meropenem 727 ≤0.06 0.12 ≤0.06 to ≥32 96.4 1.2 2.3
Minocycline 870 4 ≥32 ≤0.5 to ≥32 52.3 14.6 33.1
Pip/taz 870 8 64 ≤0.06 to ≥256 73.9 16.1 10.0
Tigecycline 870 0.25 0.5 ≤0.008 to 4 99.8 0.2 0.0
Non-ESBL K. pneumoniae
Amikacin 1917 2 8 ≤0.5 to ≥128 93.4 1.8 4.8
Amoxi/clav 1917 4 ≥64 0.25 to ≥64 67.5 10.0 22.5
Cefepime 1917 ≤0.5 16 ≤0.5 to ≥64 87.7 2.8 9.4
Ceftazidimea 1917 ≤8 32 ≤1 to ≥64 - - 17.2
Ceftriaxone 1917 ≤0.06 ≥128 ≤0.06 to ≥128 77.1 1.4 21.5
Imipenem 275 0.5 0.5 ≤0.06 to ≥32 98.9 0.0 1.1
Levofloxacin 1917 0.06 ≥16 ≤0.008 to ≥16 80.1 2.1 17.7
Meropenem 1642 ≤0.06 0.25 ≤0.06 to ≥32 94.6 1.0 4.4
Minocycline 1917 4 ≥32 ≤0.5 to ≥32 65.8 11.1 23.1
Pip/taz 1917 4 ≥256 ≤0.06 to ≥256 79.6 6.2 14.2
Tigecycline 1917 0.5 1 ≤0.008 to ≥32 96.9 2.3 0.8
ESBL K. pneumoniae
Amikacin 1045 8 ≥128 ≤0.5 to ≥128 71.2 8.3 20.5
Amoxi/clav 1045 32 ≥64 ≤0.12 to ≥64 13.1 30.6 56.3
Cefepime 1045 32 ≥64 ≤0.5 to ≥64 29.2 12.1 58.8
Ceftazidimea 1045 32 ≥64 ≤2 to ≥64 - - 81.1
Ceftriaxone 1045 ≥128 ≥128 ≤0.06 to ≥128 1.0 1.2 97.8
Imipenem 199 0.5 1 ≤0.06 to 16 96.0 2.5 1.5
Levofloxacin 1045 8 ≥16 ≤0.008 to ≥16 38.2 5.5 56.4
Meropenem 846 ≤0.06 2 ≤0.06 to ≥32 89.0 2.4 8.6
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Table 1 Antimicrobial activity against Gram-negative organisms collected from Latin America (2004 – 2010) (Continued)
Minocycline 1045 8 ≥32 ≤0.5 to ≥32 49.0 17.1 33.9
Pip/taz 1045 64 ≥256 0.12 to ≥256 34.5 20.8 44.7
Tigecycline 1045 0.5 2 0.03 to 16 93.7 4.9 1.4
K. oxytoca
Amikacin 311 2 8 ≤0.5 to ≥128 94.9 1.6 3.5
Amoxi/clav 311 4 32 0.25 to ≥64 69.1 11.9 19.0
Cefepime 311 ≤0.5 16 ≤0.5 to ≥64 85.5 5.8 8.7
Ceftazidimea 311 ≤8 32 ≤1 to ≥64 - - 20.9
Ceftriaxone 311 0.12 ≥128 ≤0.06 to ≥128 68.5 2.9 28.6
Imipenem 76 0.5 0.5 ≤0.06 to 1 100 0.0 0.0
Levofloxacin 311 0.06 ≥16 ≤0.008 to ≥16 81.0 1.3 17.7
Meropenem 235 ≤0.06 0.12 ≤0.06 to 16 97.4 1.3 1.3
Minocycline 311 2 16 ≤0.5 to ≥32 77.5 10.3 12.2
Pip/taz 311 2 128 ≤0.06 to ≥256 83.6 6.1 10.3
Tigecycline 311 0.25 1 0.06 to 4 97.7 2.3 0.0
Enterobacter spp.
Amikacin 2804 2 32 ≤0.5 to ≥128 89.2 4.4 6.5
Amoxi/clav 2804 ≥64 ≥64 ≤0.12 to ≥64 4.7 3.0 92.3
Cefepime 2804 ≤0.5 ≥64 ≤0.5 to ≥64 81.4 4.6 14.1
Ceftazidimea 2804 ≤8 ≥64 ≤1 to ≥64 - - 40.5
Ceftriaxone 2804 1 ≥128 ≤0.06 to ≥128 51.9 2.6 45.5
Imipenem 493 0.5 1 ≤0.06 to ≥32 95.9 2.6 1.4
Levofloxacin 2804 0.12 ≥16 ≤0.008 to ≥16 78.2 3.1 18.8
Meropenem 2311 ≤0.06 0.5 ≤0.06 to ≥32 94.3 1.9 3.8
Minocycline 2804 4 ≥32 ≤0.5 to ≥32 61.9 17.7 20.3
Pip/taz 2804 4 ≥256 ≤0.06 to ≥256 70.1 11.7 18.1
Tigecycline 2804 0.5 2 ≤0.008 to ≥32 96.0 3.5 0.5
S. marcescens
Amikacin 1126 2 64 ≤0.5 to ≥128 82.6 7.2 10.2
Amoxi/clav 1126 ≥64 ≥64 ≤0.12 to ≥64 4.4 2.9 92.6
Cefepime 1126 ≤0.5 32 ≤0.5 to ≥64 83.6 3.7 12.7
Ceftazidimea 1126 ≤8 32 ≤1 to ≥64 - - 17.5
Ceftriaxone 1126 0.5 ≥128 ≤0.06 to ≥128 67.8 3.4 28.9
Imipenem 229 0.5 1 ≤0.06 to 8 91.7 6.1 2.2
Levofloxacin 1126 0.25 4 ≤0.008 to ≥16 86.2 4.4 9.3
Meropenem 897 ≤0.06 0.25 ≤0.06 to 8 96.2 1.8 2.0
Minocycline 1126 4 16 ≤0.5 to ≥32 61.3 23.6 15.1
Pip/taz 1126 2 64 ≤0.06 to ≥256 84.0 6.9 9.1
Tigecycline 1126 1 2 ≤0.008 to 16 95.5 3.7 0.8
H. influenzae
Amoxi/clav 908 0.5 1 ≤0.12 to 16 99.3 0.0 0.7
Ampicillin 908 ≤0.5 16 ≤0.5 to ≥64 78.7 2.5 18.7
Cefepime 908 ≤0.5 ≤0.5 ≤0.5 to 8 99.6 – –
Ceftazidimeb 902 ≤8 ≤8 ≤8 to 16 – – –
Ceftriaxone 908 ≤0.06 ≤0.06 ≤0.06 to 2 100 – –
Imipenem 217 0.5 1 ≤0.06 to 4 100 – –
Levofloxacin 908 0.015 0.03 ≤0.008 to 2 100 – –
Meropenem 691 ≤0.06 0.12 ≤0.06 to 0.5 100 – –
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Table 1 Antimicrobial activity against Gram-negative organisms collected from Latin America (2004 – 2010) (Continued)
Minocycline 908 ≤0.5 1 ≤0.5 to 16 98.7 0.8 0.6
Pip/taz 908 ≤0.06 ≤0.06 ≤0.06 to 4 99.7 0.0 0.3
Tigecycline 908 0.12 0.25 ≤0.008 to 0.5 98.8 – –
A. baumannii
Amikacin 1806 64 ≥128 ≤0.5 to ≥128 30.4 12.0 57.6
Cefepime 1806 32 ≥64 ≤0.5 to ≥64 25.3 14.4 60.3
Ceftazidime 1806 ≥64 ≥64 ≤1 to ≥64 18.5 7.8 73.8
Ceftriaxone 1806 ≥128 ≥128 ≤0.06 to ≥128 10.5 11.1 78.4
Imipenem 307 2 ≥32 ≤0.06 to ≥32 62.5 3.9 33.6
Levofloxacin 1806 8 ≥16 ≤0.008 to ≥16 20.9 11.4 67.8
Meropenem 1499 ≥32 ≥32 ≤0.06 to ≥32 33.9 5.5 60.6
Minocycline 1806 ≤0.5 8 ≤0.5 to ≥32 89.4 4.6 6.0
Pip/taz 1806 ≥256 ≥256 ≤0.06 to ≥256 18.7 9.1 72.2
Tigecycline 1806 0.5 2 ≤0.008 to ≥32 – – –
P. aeruginosa
Amikacin 2734 4 ≥128 ≤0.5 to ≥128 71.8 8.1 20.0
Cefepime 2734 8 ≥64 ≤0.5 to ≥64 59.8 15.2 25.1
Ceftazidime 2734 ≤8 ≥64 ≤1 to ≥64 54.9 10.6 34.5
Imipenem 461 1 16 0.12 to ≥32 66.8 15.0 18.2
Levofloxacin 2734 2 ≥16 0.015 to ≥16 52.6 6.1 41.4
Meropenem 2273 2 ≥32 ≤0.06 to ≥32 64.2 9.6 26.2
Minocycline 2734 16 ≥32 ≤0.5 to ≥32 – – –
Pip/taz 2734 16 ≥256 ≤0.06 to ≥256 75.3 0.0 24.7
Tigecycline 2734 8 ≥32 ≤0.008 to ≥32 – – –
S, susceptible; I, intermediate; R, resistant; amoxi/clav, amoxicillin-clavulanate; pip/taz, piperacillin-tazobactam.
– No CLSI breakpoints available.
a The ceftazidime testing range against the Enterobacteriaceae started at 8 μg/mL, therefore susceptible and intermediate classifications can not be calculated.
b The ceftazidime testing range against H. influenzae started at 8 μg/mL, therefore a susceptible classification can not be calculated.
c 0.04%, 1 isolate, collected in 2009. The isolate was collected in Mexico in 2009 from a male inpatient. The isolate was also resistant to amoxicillin-clavulanate,
ampicillin, ceftriaxone, and minocycline.
Fernández-Canigia and Dowzicky Annals of Clinical Microbiology and Antimicrobials 2012, 11:29 Page 5 of 9
http://www.ann-clinmicrob.com/content/11/1/29producing K. pneumoniae displayed higher resistance
levels to carbapenemes than E. coli in all countries
(Table 2).
Amikacin, carbapenems and tigecycline were the
most active agents against K. oxytoca (>94% susceptibi-
lity) and Enterobacter spp. (>89% susceptibility).
Against isolates of S. marcescens the carbapenems and
tigecycline were the most active agents (>91% suscepti-
bility) (Table 1). Among these three species rates of
susceptibility to the carbapenems were ≥90% in all
countries where data were available, with the exception
of susceptibility to meropenem among isolates of Enter-
obacter spp. collected in Guatemala and Honduras
(79.0% and 85.3%, respectively) and susceptibility to
imipenem among isolates of S. marcescens from Mexico
(88.5%) (Table 2).
Almost all of antimicrobials in the panel were active
against H. influenzae with susceptibility varying from
78.7% for ampicillin to 100% for ceftriaxone, imipenem,
levofloxacin, and meropenem (Table 1). Almost 20% of
isolates (181/908) were β-lactamase producers.For A. baumannii susceptibility was less than 50% for
seven of the nine antimicrobial agents (Table 1). The
most active agents were minocycline (89.4%, MIC90
8 μg/mL) and imipenem (62.5%, MIC90 ≥32 μg/mL).
Tigecycline showed good activity against A. baumannii:
although no breakpoints are available for this agent,
95.8% of the isolates displayed an MIC ≤2 μg/mL. Low
rates of carbapenem susceptibility were observed in
most countries (Table 2); the lowest rates were reported
for meropenem among isolates from Argentina (15.0%)
and Panama (16.7%). A total of 600 isolates (33.2%) were
multidrug-resistant, among them the MIC90 for minocy-
cline and tigecycline were 8 and 2 μg/mL, respectively.
Among P. aeruginosa collected the most active agents
were piperacillin-tazobactam, with 75.3% of isolates sus-
ceptible (MIC90 ≥256 μg/mL), and amikacin with 71.8%
(MIC90 ≥128 μg/mL) (Table 1).
Discussion
This study reports on rates of antimicrobial susceptibili-















Escherichia coli Klebsiella pneumoniae
Figure 1 Percentage of Escherichia coli and Klebsiella pneumoniae isolates identified as ESBL producers in each Latin American countrya
involved in T.E.S.T. (2004–2010). E. coli N values: Argentina, 101/769; Brazil, 43/247; Chile, 94/271; Colombia, 58/519; Guatemala, 81/263;
Honduras, 31/77; Mexico, 398/1044; Panama, 16/100; Venezuela, 32/218; Latin America, 870/3581. K. pneumoniae N values: Argentina, 270/694;
Brazil, 105/214; Chile, 147/243; Colombia, 81/432; Guatemala, 96/189; Honduras, 55/75; Mexico, 191/754; Panama, 35/89; Venezuela, 36/209; Latin
America, 1045/2962. a Data from El Salvador, Jamaica and Nicaragua are not included in the analysis by country because fewer than 50 isolates
were collected; however, their data are included in the total for Latin America.
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It provides an update to the work of Rossi et al. [7] who
reported on Gram-negative and Gram-positive orga-
nisms collected as part of T.E.S.T. between 2004 and
2007. The isolates reported on by Rossi et al. [7] are also
included in the dataset studied in this report. Rates of
ESBL-producing E. coli and K. pneumoniae are similar
to the mentioned study and are also similar to those
reported by Villegas et al. [3] for Latin American isolates
collected in 2008 as part of the SMART study.
This study shows important variations in the rate of
ESBL production by country, reaching values around
40% in E. coli and >50% for K. pneumoniae, which are
similar to those observed in the Asia/Pacific region by
Farrell et al. [12] for both organisms and by Hawser et al.
2009 [13] for E. coli. However, it should be noted that
these rates may be affected by the type of infection and
population analyzed in each particular center or even by
ward [2]. Considering that these are common nosocomial
pathogens causing severe morbidity and mortality in cri-
tically ill patients and that the available choices of anti-
biotic treatments for these microorganisms are seriously
reduced, there is increasing clinical concern for success-
ful patient management where ESBL isolates are preva-
lent. Antimicrobial susceptibility rates were lower among
ESBL-producing isolates when compared with non-ESBL
producers with the exception of tigecycline, imipenem
and meropenem where little or no changes in susceptibi-
lity (<6.0%) were observed between both groups. ESBL-
producing K. pneumoniae are frequently associated withmultidrug resistance [14]. In particular, susceptibility to
commonly-used antimicrobials including piperacillin-
tazobactam and fluoroquinolones was reduced among
ESBL-producing isolates. The worrying increase in resist-
ance to these antibiotics among ESBL-producing orga-
nisms has been associated with the simultaneous presence
of other resistance determinants [15-17]. The most com-
mon risk factor for resistance to fluoroquinolones in
ESBL-producing strains is a previous history of high-level
consumption of both extended-spectrum cephalosporin
and quinolone antibiotics. These antibiotics are widely
used in the region: Wirth et al. reported an increased use
of fluoroquinolones in Latin America over a period of 10
years (1997–2007), where in some countries consumption
doubled or even tripled [18].
It has been previously reported that tigecycline and
carbapenems, along with amikacin, are highly active
against the Enterobacteriaceae collected from countries
in Latin American [19,20]. In the current study, suscep-
tibility to tigecycline ranged between 99.8% against
ESBL-producing E. coli to 93.7% against ESBL-
producing K. pneumoniae. Imipenem susceptibility ran-
ged between 100% against K. oxytoca to 91.7% against
S. marcescens and meropenem susceptibility ranged be-
tween 98.6% against non-ESBL-producing E. coli to
89.0% against ESBL-producing K. pneumoniae. The
range of tigecycline MICs was greater than reported by
Rossi et al. [7] against E. coli, K. pneumoniae, and Enter-
obacter spp.; however, this was due to single isolates at
the top of the testing range (MIC ≥32 mg/L).
Table 2 Antimicrobial susceptibility (%S) to the carbapenems among Gram-negative organisms collected from
individual countries (2004 – 2010)
Country
Antimicrobial Argentina Brazil Chile Colombia Guatemala Honduras Mexico Panama Venezuela
non-ESBL E. coli
Imipenem N 216/219 40/40 47/47 67/71 - - 64/64 - 21/21
%S 98.6 100 100 94.4 - - 100 - 100
Meropenem N 448/449 164/164 130/130 386/390 174/182 45/46 569/582 84/84 165/165
%S 99.8 100 100 99.0 95.6 97.8 97.8 100 100
ESBL E. coli
Imipenem N 28/29 10/10 29/29 17/18 - - 51/52 - -
%S 96.6 100 100 94.4 - - 98.1 -
Meropenem N 71/72 32/33 65/65 38/40 76/81 30/31 337/346 16/16 27/29
%S 98.6 97.0 100 95.0 93.8 96.8 97.4 100 93.1
non-ESBL K. pneumoniae
Imipenem N 120/121 17/17 29/29 34/35 - - 47/47 - 10/10
%S 99.2 100 100 97.1 - - 100 - 100
Meropenem N 297/303 88/92 63/67 290/316 83/93 16/20 495/516 53/54 156/163
%S 98.0 95.7 94.0 91.8 89.2 80.0 95.9 98.1 95.7
ESBL K. pneumoniae
Imipenem N 91/93 20/23 35/35 16/18 - - 19/19 - -
%S 97.8 87.0 100 88.9 - - 100 - -
Meropenem N 170/177 78/82 102/112 47/63 76/96 50/55 160/172 32/35 28/31
%S 96.0 95.1 91.1 74.6 79.2 90.9 93.0 91.4 90.3
K. oxytoca
Imipenem N 32/32 - - 13/13 - - 11/11 - -
%S 100 - - 100 - - 100 - -
Meropenem N 38/38 17/17 15/15 37/38 - - 106/110 - -
%S 100 100 100 97.4 - - 96.4 - -
Enterobacter spp.
Imipenem N 210/222 44/47 58/58 56/59 - - 58/58 - 25/25
%S 94.6 93.6 100 94.9 - - 100 - 100
Meropenem N 494/502 187/195 161/171 347/384 83/105 29/34 622/651 66/70 176/183
%S 98.4 95.9 94.2 90.4 79.0 85.3 95.5 94.3 96.2
S. marcescens
Imipenem N 83/91 18/20 30/31 37/41 - - 23/26 - 10/11
%S 91.2 90.0 96.8 90.2 - - 88.5 - 90.9
Meropenem N 203/210 77/78 70/71 138/144 42/45 14/15 220/234 25/25 69/70
%S 96.7 98.7 98.6 95.8 93.3 93.3 94.0 100 98.6
A. baumannii
Imipenem N 72/148 13/30 35/39 21/35 - - 30/30 - 7/11
%S 48.6 43.3 89.7 60.0 - - 100 - 63.6
Meropenem N 48/321 29/118 37/139 95/220 43/141 14/51 202/333 8/48 21/96
%S 15.0 24.6 27.0 43.2 30.4 27.5 60.7 16.7 21.9
a Data on El Salvador, Jamaica and Nicaragua not included in the analysis by country because fewer than 50 isolates collected.
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been observed across Latin America among members of
the Enterobacteriaceae. The situation may not appear as
poor for imipenem, with higher rates of susceptibilityreported. However, it should be noted that imipenem
susceptibility testing stopped in 2006 and switched to
meropenem, meaning that the results for meropenem
give a more current picture of carbapenem susceptibility
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http://www.ann-clinmicrob.com/content/11/1/29in Latin America. In the late 1990s and early part of the
21st century, carbapenem resistance in Enterobacteria-
ceae was infrequent and resistance mechanisms were
related to the presence of ESBL or overproduction of
AMP-C β-lactamases associated with reduced outer
membrane permeability [21,22]. Enterobacteriaceae pro-
ducing carbapenemases were first reported in the USA
[23] and have now been reported in various parts of the
world, including several countries in Latin America
where class A carbapenemase KPC-2 enzymes are preva-
lent [5,24-26]. The results of this study, along with
reports of decreasing susceptibility to imipenem among
Klebsiella spp. in Latin America [27] demonstrate the
importance of antimicrobial resistance surveillance and
further analysis of the carbapenem-resistant Enterobac-
teriaceae identified in this dataset is warranted.
H. influenzae are frequently susceptible to available
antimicrobials. In this study susceptibility was >98% to
the agents tested, with the exception of ampicillin
(78.7% susceptible) largely due to the production of β-
lactamase. This is in agreement with the global T.E.S.T.
findings published by Garrison et al. [28].
A. baumannii is a problematic organism frequently
associated with multidrug resistance and 33.2% of the
isolates in this study were defined as such. The anti-
microbial with the highest rate of susceptibility against
the whole A. baumannii population was minocycline.
Tigecycline was also active, with 95.8% of isolates dis-
playing an MIC ≤2mg/L. These results are similar to
those reported by Rossi et al. [7] for Latin America iso-
lates collected between 2004 and 2007 and Garrison
et al. [24] who reported on a global collection from the
T.E.S.T. study collected between 2004 and 2007. Suscep-
tibility to the carbapenems was 62.5% for imipenem and
33.9% for meropenem which are lower than the global
rates reported by Garrison et al. (82.3% and 59.0%, re-
spectively) and lower than the Latin American rates
reported by Gales et al. [29] for Acinetobacter spp. col-
lected between 2001 and 2004 (86.4% and 83.6%, res-
pectively). Susceptibility also varied by country, Tognim
et al. [30] reported as part of the SENTRY study that
carbapenem resistance among Acinetobacter spp. varied
between countries within Latin America with Argentina
a particular ‘hot spot’ of resistance. Our results suggest
this is a continuing situation with the lowest rates of
susceptibility to meropenem reported among isolates
from Argentina.
Conclusions
Surveillance of antimicrobial susceptibility plays a key
role in guiding appropriate antimicrobial therapy. In this
study the carbapenems and tigecycline continue to be
active against the Enterobacteriaceae and A. baumannii;
however, there is cause for concern with carbapenemnon-susceptible isolates reported in all countries
included in this study. The in vitro activity (MIC90) of
tigecycline was similar to that reported for isolates col-
lected during Phase 3 clinical trials [31].
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